WSJ
23 Jun 2026, 05:37 UTC · 2h ago
Sanofi Multiple Sclerosis Drug Gets EU Approval
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Search tags
WSJ
23 Jun 2026, 05:37 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Search tags
What the story claims
2 claims · each scored for market impact
Cenrifki has been authorized for the treatment of secondary progressive multiple sclerosis without relapses. — Drug authorization opens a new commercial revenue stream and expands the addressable patient population.
+0.60Cenrifki was previously rejected by U.S. drug regulators. — Prior regulatory rejection suggests potential hurdles or limitations in the U.S. market, tempering the upside of the authorization.
-0.20Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Continue reading
6 related stories
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
3d ago
